Onco-Innovations Limited (CVE:ONCO)

PRESS RELEASE

published on 04/24/2026 at 00:00, 23 days 20 hours ago

Onco-Innovations Advances Polymer Testing as It Moves Its PNKP Inhibitor Technology Toward IND-Enabling Studies
Onco-Innovations Limited announces advancement in analytical method for PNKP Inhibitor Technology, strengthening formulation development and scale-up for clinical manufacturing

Onco-Innovations Limited PNKP Inhibitor Technology Analytical Method Clinical Manufacturing Formulation Development
BRIEF

published on 04/22/2026 at 00:05, 25 days 20 hours ago

Onco-Innovations finalise le développement d'une méthode clé pour le programme ONC010

Contrôle De Qualité Développement De Médicaments Onco-Innovations Méthode Analytique Détermination De La Pureté
BRIEF

published on 04/22/2026 at 00:05, 25 days 20 hours ago

Onco-Innovations Completes Key Method Development for ONC010 Program

Drug Development Quality Control Onco-Innovations Analytical Method Purity Determination
PRESS RELEASE

published on 04/22/2026 at 00:00, 25 days 20 hours ago

Onco-Innovations Announces Completion of Analytical Method Development for Monomer Intermediate 1 Supporting ONC010 Program
Onco-Innovations successfully completes milestone with Dalton Pharma Services, developing analytical method for purity determination of Intermediate 1 supporting ONC010, enhancing drug delivery system quality control

Quality Control Drug Delivery System Onco-Innovations Dalton Pharma Services Analytical Method Development
BRIEF

published on 04/18/2026 at 01:05, 29 days 19 hours ago

Onco-Innovations renforce son équipe dirigeante grâce à des nominations clés

Essais Cliniques Leadership En Biotechnologie Développement En Oncologie Nominations De Cadres Supérieurs Stratégie De Recherche
BRIEF

published on 04/18/2026 at 01:05, 29 days 19 hours ago

Onco-Innovations Enhances Leadership with Key Appointments

Clinical Trials Executive Appointments Oncology Development Research Strategy Leadership In Biotechnology
PRESS RELEASE

published on 04/18/2026 at 01:00, 29 days 19 hours ago

Onco-Innovations Strengthens Executive Leadership with Appointment of Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development
Onco-Innovations appoints Dr. Islam Mohamed as CMO and Stephen M. Novak as Chief of R&D, aiming to enhance clinical and development capabilities for advancing ONC010. Strategic leadership additions for Onco's transition to clinical-stage execution

Appointment Clinical Development R&D Onco-Innovations ONC010
BRIEF

published on 04/08/2026 at 00:05, 1 month 9 days ago

Onco-Innovations s'étend en Australie avec une nouvelle filiale et un partenariat

Essais Cliniques Recherche En Oncologie Stratégie Marketing Expansion Australienne Incitations À La R&D
BRIEF

published on 04/08/2026 at 00:05, 1 month 9 days ago

Onco-Innovations Expands into Australia with New Subsidiary and Partnership

Clinical Trials Marketing Strategy Oncology Research R&D Incentives Australian Expansion
PRESS RELEASE

published on 04/08/2026 at 00:00, 1 month 9 days ago

Onco-Innovations Executes Engagement Agreement with RDI Partners and Establishes Onco-Innovations AU Pty. Ltd. to Advance Australian Phase I Strategy
Onco-Innovations announces engagement with RDI Partners & formation of ONCO AU subsidiary in Australia to support Phase I development activities & potential eligibility for Australia's R&D Tax Incentive program

Australia Onco-Innovations RDI Partners ONCO AU Phase I Development

Published on 05/17/2026 at 15:20, 5 hours 3 minutes ago

China XLX Announces 2026 Q1 Results
Published on 05/16/2026 at 01:15, 1 day 19 hours ago

Findev Inc. Announces a New Member of the Board of Directors
Published on 05/16/2026 at 01:00, 1 day 19 hours ago

Arctic Fox Adopts Semi-Annual Reporting
Published on 05/16/2026 at 00:00, 1 day 20 hours ago

Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate
Published on 05/15/2026 at 23:10, 1 day 21 hours ago

Golden Minerals Reports First Quarter 2026 Financial Results

View all ACCESSWIRE

Published on 05/16/2026 at 16:08, 1 day 4 hours ago

The publication of the audited financial statements for 2025 will be postponed to 12 June 2026 – management does not expect any significant changes to the figures already published
Published on 05/15/2026 at 20:10, 2 days ago

CPIPG Communication Concerning Voluntary Offer on NEXT RE Shares – Provisional Results Announcement
Published on 05/15/2026 at 18:30, 2 days 1 hour ago

Designated Person Notifications
Published on 05/15/2026 at 18:30, 2 days 1 hour ago

Designated Person Notifications
Published on 05/15/2026 at 18:10, 2 days 2 hours ago

Virtual Science AI launches first AI-driven competitor activity tracking platform to support pharma asset launch success

View all EQS

Published on 05/15/2026 at 15:08, 2 days 5 hours ago

Notice of exercise of early redemption option of the subordinated note ISIN : FR0010203026
Published on 05/15/2026 at 15:00, 2 days 5 hours ago

Exercice de l’option de remboursement de l'instrument subordonné FR0010203026
Published on 05/15/2026 at 10:09, 2 days 10 hours ago

Groupe Crit : Modalités de mise à disposition des documents préparatoires à l’Assemblée Générale Mixte du 05 juin 2026.
Published on 05/14/2026 at 09:03, 3 days 11 hours ago

Coup d'envoi pour les carrières dans l'esport : 65% de la population mondiale réclame plus de formations et de parcours professionnels pour le jeu vidéo de compétition
Published on 05/13/2026 at 18:02, 4 days 2 hours ago

ALTAREA : Assemblée Générale Mixte du 4 juin 2026 MODALITES DE MISE A DISPOSITION DES DOCUMENTS PREPARATOIRES

View all LES ECHOS COMFI WIRE

News